ClinicalTrials.Veeva

Menu
N

Neuromuscular Research Center | Phoenix, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Golodirsen
Casimersen
Edaravone
WP-0512
Pregabalin
Miglustat
ATB200
Fasudil
AT2221
SRP-4045

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 15 total trials

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Sub...

Active, not recruiting
Inclusion Body Myositis
Drug: ABC008
Locations recently updated

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammator...

Enrolling
Dermatomyositis
Myositis
Biological: EFG PH20 SC
Other: PBO

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subject...

Enrolling
Inclusion Body Myositis (IBM)
Drug: Ulviprubart (ABC008)
Status recently updated

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Enrolling
Active, not recruiting
Amyotrophic Lateral Sclerosis
Drug: Fasudil (WP-0512)

The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically der...

Enrolling
Dermatomyositis
Polymyositis
Drug: Placebo
Drug: M5049 high dose

The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants w...

Active, not recruiting
Duchenne Muscular Dystrophy
Drug: SRP-4053
Drug: SRP-4045

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treat...

Enrolling
Pompe Disease (Late-onset)
Biological: Cipaglucosidase Alfa
Drug: Miglustat

Trial sponsors

Sarepta Therapeutics logo
A
Amicus Therapeutics logo
Mitsubishi Tanabe Pharma logo
M
Merck KGaA (EMD Serono) logo
Roche logo
Viatris logo
W
argenx logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems